The National Medical Products Administration recently approved the new monoclonal antibody drug Cadonilimab Injection for marketing with conditions.

Cadonilimab Injection is a new PD-1/CTLA-4 bispecific antibody drug for cancer therapy developed by Akeso Biopharma, a company based in Zhoingshan. It will provide a new treatment paths for patients with recurrent or metastatic cervical cancer who have received platinum-containing chemotherapy but failed in the past.